Abstract Background Pneumococcal disease (PD) is a group of infections that can have significant yet poorly understood impact on health-related quality life (HRQoL). This meta-analysis aims to quantify the HRQoL PD. Methods Original research studies reporting health utility, disutility, quality-adjusted year (QALY), or QALY decrement associated with PD were identified through global targeted literature review in MEDLINE (March 2023). Health utilities and QALYs converted decrements per...

Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, the only oral ADT, with limited real-world data on persistence and adherence. This retrospective study evaluates adherence of relugolix, degarelix, GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using from IBM MarketScan Research Database (Jan 2017 - Dec 2022). The (1 January 31 December 2022) was used enrollment history claims....

This study provides a contemporary assessment of the treatment patterns, health care resource utilization (HRU) and costs among metastatic castration-sensitive prostate cancer (mCSPC) patients in U.S.Adults with mCSPC were selected from Optum's de-identified Clinformatics® Data Mart Database (Commercial insurance/Medicare Advantage [COM/MA]; January 1, 2014-July 31, 2019) or Medicare Fee-for-Service (FFS; 2014-December 2017). The index date was first disease diagnosis on/after (without prior...

BackgroundStudies assessing ibrutinib's economic burden versus chemoimmunotherapy (CIT) focused on pharmacy costs but not medical costs. This study compared time to next treatment (TTNT), health care resource utilization (HRU), and total direct among patients with chronic lymphocytic leukemia (CLL) initiating front-line ibrutinib single agent (Ibr) or CIT.Materials MethodsOptum Clinformatics Extended DataMart De-Identified Databases were used identify adults ≥ 2 claims a CLL diagnosis Ibr...

The aim was to compare adherence antipsychotics (APs), healthcare resource utilization (HRU), and costs before after once-every-3-months paliperidone palmitate (PP3M) initiation in patients with schizophrenia. Medicaid data (Iowa, Kansas, Missouri; 1/2014–3/2017) were used identify adults at least one PP3M claim, ≥ 12 months of pre-index enrollment, two schizophrenia diagnoses. Adequate treatment once-monthly (PP1M) required pre-PP3M transition. Generalized estimating equations assess linear...

BACKGROUND: Adherence to antiretrovirals (ARVs) is critical achieving durable virologic suppression. OBJECTIVE: To investigate risk factors of poor adherence and the effect suboptimal on health care resource utilization (HCRU) costs in Medicaid patients. METHODS: A retrospective longitudinal study was conducted using data. Adults (aged ≥ 18 years) with human immunodeficiency virus (HIV)-1 initiating selected ARVs (index date) were identified. measured medication possession ratio (MPR)...

Objective To compare real-world treatment persistence, dose escalation, rates of opportunistic or serious infections, and healthcare costs in patients with Crohn's disease (CD) receiving vedolizumab (VDZ) vs ustekinumab (UST) the United States.

e19131 Background: Given recent advances in treatment options for mCSPC, this study assessed US real-world patterns of mCSPC patients over time. Methods: The Optum Clinformatics Extended DataMart was used to identify men with ≥2 claims PC, ≥1 claim metastasis, castration sensitivity (CS) indicator (CS diagnosis code [dx]; and no prostate-specific antigen [PSA] rise; or hormone/castration naive ≥18 months [mo] before metastasis). Index (idx) date the 1 st metastasis dx on after PC from...

Objective: This study assessed healthcare costs of first-line treatment failure (TF) in patients with chronic lymphocytic leukemia (CLL), a subtype non-Hodgkin’s lymphoma.Methods: Pre-diagnosis treatment-naïve adults ≥2 CLL diagnoses initiated on an antineoplastic agent (index date) after their first diagnosis ≥12 and ≥6 months continuous observation pre- post-index, respectively, were selected from the Truven Health MarketScan Research Databases. Patients had no solid malignancies pre-index...

This study described patients hospitalized for acute heart failure (AHF) in Japan who received intravenous (IV) diuretics and/or vasodilators as the initial therapy. The Medical Data Vision database was used to identify adult AHF during 2013–2017, were hemodynamically stable at presentation and treated with IV Treatment patterns use of cardiac rehabilitation, well outcomes (e.g., length stay [LOS], in-hospital mortality, HF-readmission) reported overall by year hospitalization. Of 30,360...

Some institutions have implemented a daratumumab intravenous rapid-infusion protocol in which patients with multiple myeloma (MM) receive their third and subsequent infusions within ~ 90 min instead of ≥ 3 h. This study sought to understand the utilization, effectiveness, infusion reactions (IRs) observed MM who received rapid infusions. Electronic medical records from Florida Cancer Specialists & Research Institute were used. Adult one or more (full dose ≤ 110 min) at later first...

"HSR24-147: Non-Optimal Treatment in Early-Line Patients With Chronic Myeloid Leukemia Phase (CML-CP) Treated Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis" published on 05 Apr 2024 by National Comprehensive Cancer Network.

e17110 Background: Relugolix (REL) is the only oral gonadotropin-releasing hormone (GnRH) antagonist available for patients (pts) with advanced PC. Other ADT options these pts include injectable GnRH degarelix (DEG) or injections implants of agonists (i.e., leuprolide, goserelin, triptorelin, histrelin). This study assessed persistence and adherence REL, DEG, in US Methods: retrospective used Merative MarketScan Research Claims Database (Commercial Medicare Supplemental; 01/2017–12/2022)....

This study assessed direct-acting oral anticoagulant (DOAC) switching/discontinuation patterns in patients with non-valvular atrial fibrillation (NVAF) 2019, by quarter (Q1-Q4), and associated socioeconomic risk factors. Adults NVAF initiating stable DOAC treatment (July 2018-December 2018) were selected from Symphony Health Solutions' Patient Transactional Datasets (April 2017-January 2021). Switching/discontinuation rates reported 2019 Q1-Q4, separately. Non-medical (NMSD) was defined as...

BACKGROUND: New guidelines for the treatment of human immunodeficiency virus (HIV) suggest that morbidity and mortality could be reduced if antiretroviral therapy (ART) was initiated immediately after diagnosis, regardless CD4 cell count. OBJECTIVE: To assess real-world time to ART initiation describe medical, pharmacy, total health care costs in 6-, 12-, 24-, 36-month periods HIV diagnosis based on among Medicaid-covered patients. METHODS: Multistate Medicaid data (January 2012-March 2017)...

<h3>Objective:</h3> To describe the effectiveness and safety of vesicular monoamine transporter 2 inhibitor deutetrabenazine (DTBZ) combined with antipsychotic agents (APs) in patients Huntington disease (HD)-related chorea a real-world setting. <h3>Background:</h3> DTBZ for HD-related have been well documented clinical trials; however, receiving APs were not included. Safety data DTBZ+AP are needed to inform practice. <h3>Design/Methods:</h3> Data collected from charts HD-associated who...

Crohn's-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim this study was assess the burden recurrent episodes care for RVF its economic impact. A retrospective observational cohort administrative US claims databases conducted. Eligible patients were female adults, with a diagnosis code Crohn's disease or without diagnosis/procedural RVF. For cohort, rates recurrence estimated using Kaplan–Meier analyses. Healthcare resource...